Pharmaceutical composition containing a mixture of proenzymes and enzymes

Abstract

Pharmaceutical composition containing a mixture of proenzymes and enzymes, containing proenzymes trypsinogen and chymotrypsinogen and enzymes ct-amylase and lipase as active substances, and one or more pharmaceutically acceptable excipients, for simultaneous, separate and subsequent administration of the composition in parenteral or transmucosal way, the composition has anti-proliferative and anti-metastatic effects to cancer tumours and is intended for therapeutic, prophylactic and anti-metastatic use in mammals.

Description

TECHNICAL FIELD[0001]The invention deals with new pharmaceutical compositions containing a mixture of proenzymes and enzymes having anti-proliferative and anti-metastatic effects.BACKGROUND ART[0002]Malignant neoplastic diseases represent a vast group of diseases that are one of the worst curable death causes. They cause 13 percent of deaths per year recently. (Jemal A. et al., CA: Cancer J. Clinic., 61, 2011, 69-90.). Occurrence of malignant tumours brings dangers given by the ability of tumour cells to change adjacent cells while new blood vessels, further supporting cells and metastases are produced.[0003]Anti-neoplastic pharmacotherapy is an important part of large spectrum of present treatment approaches. In terms of therapeutic position pharmacotherapy of neoplastic diseases is divided to adjuvant (affecting so called residual disease e.g. after a surgical operation), non-adjuvant (preceding operation and radiation treatment, aimed at tumour devitalisation and inhibition) and ...

AI Technical Summary

Benefits of technology

The invention proposes a new composition that has the ability to destroy tumour cells that have already appeared in humans or animals. This composition was designed to absorb into the body through the sublingual mucous membrane, which allows for slower and longer transfer of the substances to the liver, where they are often metabolised and deactivated. The composition can be utilized in a non-invasive way, making it easier for patients to administer and potentially even self-administer. Additionally, a new type of sublingual preparation that uses nanofibre membranes is being developed to incorporate the active substances in the composition. Overall, this invention provides a novel way to treat tumour cells and limit their propagation in the body.

Problems solved by technology

Occurrence of malignant tumours brings dangers given by the ability of tumour cells to change adjacent cells while new blood vessels, further supporting cells and metastases are produced.

We can add in general that any intervention in such a complicated and still little known system always leads to some consequences, which are however not always known or predictable or positive.

Other malignant cancer diseases show a limited response only (if any) and no efficient therapy is available against them now.

Moreover, most of the clinically approved anti-neoplastic medicines are characterized by narrow therapeutic window, which is particularly related to their high systemic toxicity (Lowenthal, R. M.; Eaton, K., Hematol. Oncol. Clin. North Am., 10, 1996, 967-90).

Resistance against anti-neoplastic medicines represents another serious problem, particularly in long-term treatment (Redmond, K. M. et al.

The fact that in 98 percent of cases it is only linked to parenteral injection or infusion administration is another disadvantage of present pharmacology of tumours by substances of biologics group.

On the other hand all principal disadvantages of parenteral administration itself remain unsolved, from higher risk of infection in the needle mark to patient non-compliance even in the link to the hospital and its qualified staff.

Images